Breast cancer 2012 - New aspects

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 7, 2012, Pages 602-615

  Kolberg, H C ^a   Luftner D ^b   Lux, M P ^c   Maass, N ^d   Schutz F ^e   Fasching, P A ^c   Fehm, T ^f   Janni, W ^g   Kummel S ^h  

^a Marien Hospital Bottrop gGmbH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h KLINIKEN ESSEN MITTE   (Germany)

Author keywords

ABCSG 12; BOLERO 2; CLEOPATRA; EMILIA; everolimus; GAIN; NSABP B34; pertuzumab; TDM 1; ZO FAST

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; LAPATINIB; LETROZOLE; MOLECULAR MARKER; NERATINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PERTUZUMAB; RALOXIFENE; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

BONE METASTASIS; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; OVERALL SURVIVAL; PHARMACOGENOMICS; PREDICTOR VARIABLE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE;

EID: 84864408104     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1315131     Document Type: Review

References (77)

1. Fasching PA, Fehm T, Janni W et al. Breast cancer therapy - a state of the art review. Geburtsh Frauenheilk: 2010; 70 875 886 10.1055/s-0030-1250437
2. Kummel S, Kolberg HC, Luftner D et al. Breast cancer 2011 - new aspects. Geburtsh Frauenheilk: 2011; 71 939 953 10.1055/s-0031-1280313
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med: 2002; 347 1233 1241 10.1056/NEJMoa022152 (Pubitemid 35176242)
4. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med: 2002; 347 1227 1232 10.1056/NEJMoa020989 (Pubitemid 35176241)
5. Bani HA, Fasching PA, Lux MM et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. Patient education and counseling: 2007; 66 311 318 10.1016/j.pec.2007.01.004 (Pubitemid 46726949)
6. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med: 2003; 349 546 553 10.1056/NEJMoa012782 (Pubitemid 36951366)
7. Kühn T. Mammakarzinom. Stellenwert des axillären Stagings. Gynäkologe: 2011; 44 999 1004
8. Galimberti V, Cole BF, Zurrida S et al. Update of International Breast Cancer Study Group trial 23-01 to compare axillary dissection versus no axillary dissection in patients with clinically node negative breast cancer and micrometastases in the sentinel node. Cancer Res: 2011; 71 102s
9. Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol: 2010; 28 2874 2880 10.1200/JCO.2009.24.7643
10. Engel J, Lebeau A, Sauer H et al. Are we wasting our time with the sentinel technique? Fifteen reasons to stop axilla dissection. Breast: 2006; 15 452 455 10.1016/j.breast.2005.05.009 (Pubitemid 43840878)
11. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA: 2011; 305 569 575 10.1001/jama.2011.90
12. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol: 2010; 11 927 933 10.1016/S1470-2045(10)70207-2
13. Arbeitsgemeinschaft für Gynäkologische Onkologie e.V. AGO Guidelines. http://www.ago-online.org last access: 2012
14. Veronesi U, Orecchia R, Luini A et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat: 2010; 124 141 151 10.1007/s10549-010-1115-5
15. Vaidya JS, Baum M, Tobias JS et al. Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. Int J Radiat Oncol, Biol, Phys: 2011; 81 1091 1097 10.1016/j.ijrobp.2010.07.1996
16. Smith GL, Xu Y, Buchholz TA et al. Partial breast brachytherapy is associated with inferior effectiveness and increased toxicity compared with whole breast irradiation in older patients. Cancer Res: 2011; 71 99s
17. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers experience. Int J Radiat Oncol, Biol, Phys: 2002; 53 868 879 (Pubitemid 34722631)
18. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet: 2005; 366 2087 2106 10.1016/S0140-6736(05)67887-7 (Pubitemid 41797643)
19. Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol: 2006; 24 3381 3387 10.1200/JCO.2006.06.1366 (Pubitemid 46638893)
20. Hughes LL, Wang M, Page DL et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol: 2009; 27 5319 5324 10.1200/JCO.2009.21.8560
21. Solin LJ, Gray R, Baehner FL et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res: 2011; 71 108s
22. Untch M, von Minckwitz G. Neoadjuvant treatment of breast cancer. Breast Care (Basel): 2011; 6 417 10.1159/000335444
23. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med: 2012; 366 299 309 10.1056/NEJMoa1111065
24. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol: 2012; 13 135 144 10.1016/S1470-2045(11)70397-7
25. Untch M, Fasching PA, Konecny GE et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol: 2011; 29 3351 3357 10.1200/JCO.2010.31.4930
26. von Minckwitz G, Untch M, Nuesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast cancer research and treatment: 2011; 125 145 156 10.1007/s10549-010-1228-x
27. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol: 2012; 10.1200/JCO.2011.38.8595
28. Gianni L, Bianchini G, Kiermaier A et al. Neoadjuvant pertuzumab and trastuzumab: biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients with HER2-positive breast cancer. Cancer Res: 2011; 71 109s 110s
29. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol: 2012; 13 25 32 10.1016/S1470-2045(11) 70336-9
30. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA). Cancer Res: 2011; 71 112s 113s
31. Fasching PA, Heusinger K, Haeberle L et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer: 2011; 11 486 10.1186/1471-2407-11-486
32. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol: 2008; 26 1275 1281 10.1200/JCO.2007.14.4147
33. Loibl S, von Minckwitz G, Blohmer JU et al. pCR as a surrogate in HER2-positive patients treated with trastuzumab. Cancer Res: 2011; 71 111s
34. Cheang MCU, Prat A, Fan C et al. PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/taxane and trastuzumab/taxane containing regimens in HER2-positive breast cancer. Cancer Res: 2011; 71 110s
35. von Minckwitz G, Kümmel S, Vogel P et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst: 2008; 100 542 551
36. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol: 2011; 22 1736 1747 10.1093/annonc/mdr304
37. von Minckwitz G, Eidtmann H, Loibl S et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol: 2011; 22 301 306 10.1093/annonc/mdq350
38. Huober J, Hanusch C, Fasching PA et al. Neoadjuvant chemotherapy of paclitaxel with or without Rad001: results of the non-responder part of the GEPARQUINTO study (GBG 44). Cancer Res: 2011; 71 105s
39. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med: 2009; 360 679 691 10.1056/NEJMoa0806285
40. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in postmenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res: 2011; 71 95s 96s
41. de Boer R, Bundred N, Eidtmann H et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST. Cancer Res: 2011; 71 96s
42. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med: 2011; 365 1396 1405 10.1056/NEJMoa1105195
43. Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol: 2008; 19 2007 2011 10.1093/annonc/mdn429
44. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol: 2002; 20 3219 3224 (Pubitemid 34831518)
45. Paterson AHG, Anderson SJ, Lembersky BC et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis. Cancer Res: 2011; 71 100s
46. Moebus V, Thomssen C, Harbeck N et al. Gain (German Adjuvant Intergroup Node Positive) study: a phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis. Cancer Res: 2011; 71 6s
47. Janni WJ, Harbeck N, Sommer H et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120 in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Res: 2011; 71 140s
48. Untch M, Fasching PA, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/ cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol: 2011; 22 1988 1998 10.1093/annonc/mdq709
49. Untch M, von Minckwitz G, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol: 2011; 22 1999 2006 10.1093/annonc/mdq713
50. Nitz U, Gluz O, Oberhoff C et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA plus trial. Cancer Res: 2011; 71 143s
51. Goss P, Smith I, OShaugnessy J et al. Results of a randomized, double-blind, multicenter, placebo-controlled study of adjuvant lapatinib in women with early-stage ErbB2-overexpressing breast cancer. Cancer Res: 2011; 71 109s
52. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med: 2012; 366 109 119 10.1056/NEJMoa1113216
53. Saura C, Garcia-Saenz JA, Xu B et al. Safety and efficacy of neratinib in combination with capecitabine in patients with ErbB2-positive breast cancer. Cancer Res: 2011; 71 225s
54. Gianni L, Romieu G, Lichinitser M et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res: 2011; 71 109s
55. Blackwell KL, Miles D, Gianni L et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol: 2012; 30 (suppl; abstr 512)
56. Xu B, Guan ZZ, Shen ZZ et al. Association of PTEN loss and PIK3CA mutations on outcome in HER2+ metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Cancer Res: 2011; 71 103s 104s
57. Colleoni M, Giobbie-Hurder A, Regan MM et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol: 2011; 29 1117 1124 10.1200/JCO.2010.31.6455
58. Paridaens RJ, Dirix LY, Beex LV et al. The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women. J Clin Oncol: 2008; 26 4883 4890 10.1200/JCO.2007.14.4659
59. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol: 2003; 21 2101 2109 10.1200/JCO.2003.04.194 (Pubitemid 46606358)
60. Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer: 2003; 39 1684 1689 (Pubitemid 36897604)
61. Bergh J, Jonsson PE, Lidbrink EK et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol: 2012; 10.1200/JCO.2011.38.1095
62. Mehta RS, Barlow WE, Albain KS et al. A Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. Cancer Res: 2011; 71 95s
63. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med: 2012; 366 520 529 10.1056/NEJMoa1109653
64. Piccart-Gebhart MJ, Noguchi S, Pritchard KI et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. J Clin Oncol: 2012; 30 (suppl; abstr 559)
65. Statistisches Bundesamt Gesundheit - Ausgaben (Lange Reihe) - Fachserie 12, Reihe 7.1.2 - 1995 bis 2012. Erschienen am: 05 04 2012; Artikelnummer: 2120712107004
66. Lux MP, Fasching PA, Loehberg CR et al. Health services research and health economy - quality care training in gynaecology, with focus on gynaecological oncology. Geburtsh Frauenheilk: 2011; 71 1046 1055 10.1055/s-0031-1280435
67. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst: 2011; 103 117 128 10.1093/jnci/djq495
68. Chereau E, Vataire AL, Laas E et al. Economic analysis of chemotherapy costs for adjuvant therapy in breast cancer in France. Cancer Res: 2011; 71 214s 215s
69. Baffert S, Cottu PH, Kirova Y et al. Burden of brain metastases in HER2-positive breast cancer: healthcare use and costs from a French observational retrospective multicenter study. Cancer Res: 2011; 71 212s 213s
70. Reed SD, Li Y, Anstrom KJ et al. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol: 2009; 27 2185 2191
71. Centers for Medicare & Medicaid Services, Office of the Actuary Updated national health expenditure projections 2009-2019. https://www.cmsgov/ Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ NationalHealthExpendData/downloads/proj2009pdf last access: September 2011
72. Hershman DL, Neugut AI, Richards CA et al. Influence of hospital factors, physician factors and type of health insurance on receipt of immediate postmastectomy reconstruction in young women with breast cancer. Cancer Res: 2011; 71 114s 115s
73. Neumann PJ, Palmer JA, Nadler E et al. Cancer therapy costs influence treatment: a national survey of oncologists. Health Affairs: 2010; 29 196 202
74. Lacey L, Chien R, Hornberger J. Cost-utility of the 21-gene breast cancer assay (Oncotype DX®) in the Irish healthcare setting. Cancer Res: 2011; 71 213s
75. Pronzato P, Plun-Favreau J. Is the 21-gene breast cancer test (Oncotype DX®) cost-effective? Cancer Res: 2011; 71 213s 214s
76. Warren JL, Yabroff KR, Meekins A et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst: 2008; 100 888 897 (Pubitemid 351881955)
77. von Minckwitz G, Blohmer JU, Costa SD et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial. Cancer Res: 2011; 71 103s